Tech

US sinks another $2.1 billion into a potential vaccine

AP Published: 2020-07-31 21:24:40

Jess O'Hara a research technician works on the process of testing antibodies to see if they bind to the virus, in the laboratory at Imperial College in London, Thursday, July 30, 2020. [Photo: AP]

Jess O’Hara a research technician works on the process of testing antibodies to see if they bind to the virus, in the laboratory at Imperial College in London, Thursday, July 30, 2020. [Photo: AP]

Pharma giants GlaxoSmithKline and Sanofi Pasteur have announced they will supply 100 million doses of its experimental COVID-19 vaccine to the United States as governments buy up supplies in hopes something will work.

The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery of its vaccine,” the companies said in a statement. Sanofi will get the bulk of the funds.

The U.S. government has a further option for the supply of an additional 500 million doses longer term as part of its Operation Warp Speed program.

“The portfolio of vaccines being assembled for Operation Warp Speed increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” U.S. Health and Human Services Secretary Alex Azar said in a statement. “Today’s investment supports the Sanofi and GSK adjuvanted product all the way through clinical trials and manufacturing, with the potential to bring hundreds of millions of safe and effective doses to the American people.”

Earlier this week the British government signed a deal for 60 million doses of a potential coronavirus vaccine that could start to be rolled out in the first half of next year.

Britain’s GSK and France’s Sanofi’s vaccine prospect is based on the existing DNA-based technology that is used to produce Sanofi’s seasonal flu vaccine. It is one of several vaccines in development.

“The global need for a vaccine to help prevent COVID-19 is massive, and no single vaccine or company will be able to meet the global demand alone,” said Thomas Triomphe, executive vice president of Sanofi Pasteur.

The companies said discussions are ongoing with the European Commission.

Related posts

Beijing calls for scientific explanations for where COVID-19 originated

epoekie

China denounces COVID-19 Accountability Act proposed by U.S. senator

epoekie

U.S. health expert recalls Chinese peers’ guidance on fighting COVID-19

epoekie

Why Watson data platform can be the iTunes for your Big Data

epoekie

Facebook’s News Feed experiment panics publishers

epoekie

Dr. Fauci, WHO and Five Eyes all reject ‘Chinese lab theory’

epoekie

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More